All News
Upadacitinib FDA Approved for Ankylosing Spondylitis
Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.
Read Article
$30 Billion and Counting (4.29.2022)
Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.
Read Article
Prolonged TNF Inhibitor Use Delays Sacroiliac Progression
While tumour necrosis factor inhibitors (TNFi) have been shown to alter/retard X-ray outcomes in peripheral inflammatory arthritis, the inhibitor effects of TNFi on axial skeletal progression in spondylitis has been difficult to prove, owing to difficulties in study design, identifying best cohorts and a presumed slower rate of change in the spine.
Read Article
Rheumatologic diagnosis through hand exam by Dr. Sarah Chung @ACPinternists #rheumatology #rheumtwitter #MedEd #rheumatoidarthritis #BJHM #Hospitalmedicine #IM2022 #MedTwitter 👇🏽 https://t.co/qR4zNa4NcX
Brown Journal of Hospital Medicine BrownJHM ( View Tweet)
Patient with new onset Colitis while on secukinumab, but is this drug-induced?
https://t.co/tpipGFOHI4 https://t.co/h4QujJdU8O
Links:
Dr. John Cush RheumNow ( View Tweet)
Leflunomide responses in #RA assoc w/ high metabolite levels (A77 1726). In 115 LEF Rx Pts, 40% had LDAS/remission. A77 1726 levels neg correlation w/ DAS28-ESR (r = − 0.42, p < 0.001). Levels >10µg/mL & LDAS PPV 70%; NPV 93% https://t.co/V32wUGVWLM https://t.co/L9DwZBwet9
Links:
Dr. John Cush RheumNow ( View Tweet)
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/NiPTbknD57 https://t.co/HOC2Bev4R6
Links:
Dr. John Cush RheumNow ( View Tweet)
We completed a whole month of super-charged, focused coverage & education on #PsA.THANKS to the many mavens who contributed! In PSA - "Unless someone like you cares a whole awful lot, nothing is going to get better. It’s not." -Dr. Seuss, The Lorax https://t.co/Y58klwbS4V https://t.co/f2pnuypwyr
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 33 #RA pts finds nearly half had peripheral neuropathy (48.5%); sensorimotor in 64.7%, motor in 17.6%. Neuropathy was NOT associated with age, gender, disease activity, functionality, or falls https://t.co/r2aQI2cm27 https://t.co/OOQlWkCAft
Links:
Dr. John Cush RheumNow ( View Tweet)
Prolonged TNF Inhibitor Use Delays Sacroiliac Progression
https://t.co/dz4d8q8XSy https://t.co/NWCAb0OH7B
Links:
Dr. John Cush RheumNow ( View Tweet)
Intraarticular Steroids in Hip Osteoarthritis - Do They Work?
https://t.co/AP9jo96xQo https://t.co/tYvP20Qpqh
Links:
Dr. John Cush RheumNow ( View Tweet)
Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion about two important studies.
https://t.co/RjFRFt6oJQ https://t.co/zOxCDC1atS
Links:
Dr. John Cush RheumNow ( View Tweet)
Biologics for JIA? Not So Fast, Say Insurers
It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.
https://t.co/w4A5sgv3fU https://t.co/coVh3zui2z
Links:
Dr. John Cush RheumNow ( View Tweet)
Arthritis Predicts Hepatic Fibrosis in Hemochromatosis
https://t.co/AHnRkvq2wo https://t.co/zbl3HQRZCX
Links:
Dr. John Cush RheumNow ( View Tweet)
Today the FDA expanded the indications for upadacitinib (Rinvoq) to include ankylosing spondylitis - specifically for adults w/ active ankylosing spondylitis after failing a TNF blockers or other DMARDs. https://t.co/A9QhT98Djj
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of PCP Dx irritable bowel dz; 459 randomised to 8 weeks of oral antispasmodics or diet (low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP). Better responses with diet (71% vs 61%; p=0.03). Better adherence w/ diet. https://t.co/gmn45yQmuB https://t.co/8SP5Vfx71z
Links:
Dr. John Cush RheumNow ( View Tweet)
Nature study shows videoconferencing inhibits creativity (idea generation) because it focuses communicators on a screen, which prompts a narrower cognitive focus. Yet, virtual interaction might increase decision quality. https://t.co/0yTEcmtKye https://t.co/ruwOj9qJ9J
Dr. John Cush RheumNow ( View Tweet)
Pregnancy outcomes in systemic sclerosis (SSc) studied in 154 pregnancies from SSc, SLE, APS, & controls (2008 to 2019). Adverse Preg Outcomes APO significantly higher in SSc vs HC (61% vs 10%) w/ more miscarriages, preeclampsia, SGA & preterm births https://t.co/P3uksmJy6V https://t.co/nTtgwjdGgL
Links:
Dr. John Cush RheumNow ( View Tweet)
Miss this week’s Tuesday Night Rheumatology? We’ve got you covered.
https://t.co/TuBeZTWG9d https://t.co/qWWBSXKKSW
Links:
Dr. John Cush RheumNow ( View Tweet)
Perplexing Oligoarthritis, +FHx, But no psoriasis
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/ljZ1cStNTy https://t.co/8RMFFWjDEP
Links:
Dr. John Cush RheumNow ( View Tweet)